Arjen’s main research interests include the pathophysiology and treatment of severe malaria, antimalarial drug resistance and the improvement of intensive care practice in developing countries. A major focus of Arjen’s current work is to understand the biology of artemisinin resistant P. falciparum, and find ways to contain artemisinin-resistant malaria. His team, based at MORU, was the first to perform a comparative trial which unambiguously showed resistance of P. falciparum to artemisinins in Western Cambodia. Under the banner of the Tracking Resistance to Artemisinin Collaboration (TRAC), they are working with other international groups to further characterise this resistance phenotype and identify underlying molecular determinants of artemisinin resistance. This team is also involved in finding new treatments for patients that are infected with resistant parasites and contributing to falciparum malaria elimination efforts in Southeast Asia to minimise the threat of artemisinin resistance to global malaria control. In addition to this focus on malaria, he is involved in the coordination of a dedicated effort to improve intensive care medicine in developing countries in Asia, through teaching as well as the systematic implementation of cost-effective interventions and their assessment.